The Use of Meta-analysis in Pharmacoepidemiology

Pharmacoepidemiology, Fifth Edition

Volumn , Issue , 2012, Pages 723-756

  Berlin, Jesse A ^a   Cepeda, Soledad ^a   Kim, Carin J ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cumulative meta analysis; Heterogenicity; Indirect comparison; Literature search; Measures of association; Meta analysis; Mixed treatment comparison; Prospective meta analysis; Publication bias; Rare event

Indexed keywords

EID: 84888698754     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119959946.ch40     Document Type: Chapter

References (194)

1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 177-88.
2. Last JM. A Dictionary of Epidemiology, 2nd edn. New York, NY: Oxford University Press, 1988.
3. Berlin JA, Longnecker MP, Greenland S. Metaanalysis of epidemiologic dose -response data. Epidemiology 1993; 4: 218-28.
4. Feinstein AR. Para-analysis, faute de mieux, and the perils of riding on a data barge. J Clin Epidemiol 1989; 42: 929-35.
5. Shapiro S. Is meta -analysis a valid approach to the evaluation of small effects in observational studies? J Clin Epidemiol 1997; 50: 223-9.
6. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta -analysis of observational studies. BMJ 1998; 316: 140-4.
7. Buffl er PA. The evaluation of negative epidemiologic studies: the importance of all available evidence in risk characterization. Regul Toxicol Pharmacol 1989; 9: 34-43.
8. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med 1987; 316: 450-5.
9. L'Abbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987; 107: 224-33.
10. Colditz GA, Burdick E, Mosteller F. Heterogeneity in meta-analysis of data from epidemiologic studies: a commentary. Am J Epidemiol 1995; 142: 371-82.
11. Berlin JA. Invited commentary: benefi ts of heterogeneity in meta -analysis of data from epidemiologic studies. Am J Epidemiol 1995; 142: 383-7.
12. Bero LA, Rennie D. The Cochrane Collaboration - preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA 1995; 274: 1935-8.
13. Doyle J, Waters E, Noonan E, Royle N, Kowalski K, Gill C, et al.Working with the Campbell Collaboration to produce reviews of relevance to public health across the education, justice and social welfare sectors. J Public Health (Oxf) 2010; 32: 138-40.
14. Dickersin K, Berlin JA. Meta-analysis: state -of-thescience. Epidemiol Rev 1992; 14: 154-76.
15. Mulrow CD. The medical review article: state of the science. Ann Intern Med 1987; 106: 485-8.
16. Oxman AD, Guyatt GH. Guidelines for reading literature reviews. Can Med Assoc J 1988; 138: 697-703.
17. Chalmers I. Improving the quality and dissemination of clinical research. In: Lock S, ed. The Future of Medical Journals: in Commemoration of 150 Years of the British Medical Journal. London, England: British Medical Society, 1991, pp. 127-46.
18. Kass EH. Reviewing reviews. In: Warren KS, ed. Coping with the Biomedical Literature: a Primer for the Scientist and the Clinician. New York, NY: Praeger, 1981, pp. 71-91.
19. Huth EJ. Needed: review articles with more scientifi c rigor. Ann Intern Med 1987; 106: 470-1.
20. Canner PL. An overview of six clinical trials of aspirin in coronary heart disease. Stat Med 1987; 6: 255-67.
21. Longnecker MP, Berlin JA, Orza MJ, Chalmers TC. A meta -analysis of alcohol consumption in relation to risk of breast cancer. JAMA 1988; 260: 652-6.
22. Berlin JA, Colditz GA. A meta -analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 1990; 132: 612-28.
23. Morgenstern H, Glazer WM, Niedzwiecki D, Nourjah P. The impact of neuroleptic medication on tardive dyskinesia: a meta -analysis of published studies. Am J Pub Health 1987; 77: 717-24.
24. Larsson SC, Orsini N, Wolk A. Vitamin B6 and risk of colorectal cancer: a meta -analysis of prospective studies. JAMA 2010; 303: 1077-83.
25. Stroup DF, Berlin JA, Morton SC, Olkin I,Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
26. Berlin JA, Colditz GA. The role of meta -analysis in the regulatory process for foods, drugs, and devices. JAMA 1999; 281: 830-4.
27. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose -response data, with applications to meta -analysis. Am J Epidemiol 1992; 135: 1301-9.
28. Greenland S, Salvan A. Bias in the one -step method for pooling study results. Stat Med 1990; 9: 247-52.
29. Fleiss JL, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: a critique. J Clin Epidemiol 1991; 44: 127-39.
30. O'Neill RT, Anello C. Does research synthesis have a place in drug regulatory policy? Synopsis of issues: assessment of effi cacy and drug approval. Clin Res Regul Aff 1996; 13: 23-9.
31. Poole C, Greenland S. Random-effects meta -analyses are not always conservative. Am J Epidemiol 1999; 150: 469-75.
32. Stroup DF, Berlin JA, Morton SC, Olkin I,Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology -A proposal for reporting. JAMA 2000; 283: 2008-12.
33. Crowe BJ, Xia HA, Berlin JA, Watson DJ, Shi H, Lin SL, et al. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clin Trials 2009; 6: 430-40.
34. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta - analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA 1992; 268: 240-8.
35. Gartlehner G, Moore CG. Direct versus indirect comparisons: a summary of the evidence. Int J Technol Assess Health Care 2008; 24: 170-7.
36. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105-24.
37. Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009; 338: b1147.
38. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta - analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65-W94.
39. Begg CB, Berlin JA. Publication bias and dissemination of clinical research. J Natl Cancer Inst 1989; 81: 107-15.
40. Andrews TC, Reimold SC, Berlin JA, Antman EM. Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta -analysis of randomized control trials. Circulation 1991; 84 (Suppl): III 236-44.
41. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337: 867-72.
42. Moher D, Berlin J. Improving the reporting of randomised controlled trials. In: Maynard A, Chalmers I, eds. Non-random Refl ections on Health Services Research. London: BMJ Publishing Group, 1997, pp. 250-71.
43. Dickersin K, Min YI, Meinert CL. Factors infl uencing publication of research results. Follow -up of applications submitted to two institutional review boards. JAMA 1992; 267: 374-8.
44. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990; 263: 1385-9.
45. Dickersin K, Min YI. NIH clinical trials and publication bias. Online J Curr Clin Trials 1993; Doc No 50.
46. Chalmers I. Underreporting research is scientifi c misconduct. JAMA 1990; 263: 1405-8.
47. Chalmers TC, Frank CS, Reitman D. Minimizing the three stages of publication bias. JAMA 1990; 263: 1392-5.
48. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997; 315: 640-5.
49. Ioannidis JP. Effect of the statistical signifi cance of results on the time to completion and publication of randomized effi cacy trials. JAMA 1998; 279: 281-6.
50. Berlin JA, Begg CB, Louis TA. An assessment of publication bias using a sample of published clinical trials. J Am Stat Assoc 1989; 84: 381-92.
51. Sutton AJ, Abrams KR, Jones DR. Generalized synthesis of evidence and the threat of dissemination bias: the example of electronic fetal heart rate monitoring (EFM). J Clin Epidemiol 2002; 55: 1013-24.
52. Chalmers TC, Berrier J, Sacks HS, Levin H, Reitman D, Nagalingam R. Meta-analysis of clinical trials as a scientifi c discipline. II: Replicate variability and comparison of studies that agree and disagree. Stat Med 1987; 6: 733-44.
53. Early Breast Cancer Trialists' Collaborative Group. Treatment of Early Breast Cancer, Vol. I. Worldwide Evidence. New York, NY: Oxford University Press, 1990.
54. Sutton AJ, Duval S, Tweedie R, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta -analyses. BMJ 2000; 320: 1574-7.
55. Hetherington J, Dickersin K, Chalmers I, Meinert CL. Retrospective and prospective identifi cation of unpublished controlled trials: lessons from a survey of obstetricians and pediatricians. Pediatrics 1989; 84: 374-80.
56. Gotzsche PC. Reference bias in reports of drug trials. BMJ Clin Research Ed 1987; 295: 654-6.
57. Egger M, Zellweger -Zahner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997; 350: 326-9.
58. Moher D, Fortin P, Jadad AR, Juni P, Klassen T, Le Lorier J, et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet 1996; 347: 363-6.
59. Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med 1986; 1: 155-8.
60. Hemminki E. Study of information submitted by drug companies to licensing authorities. BMJ 1980; 280: 833-6.
61. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med 1996; 124: 485-9.
62. O'Connor AB. The need for improved access to FDA reviews. JAMA 2009; 302: 191-3.
63. Chalmers TC. Problems induced by meta -analyses. Stat Med 1991; 10: 971-9.
64. Chalmers TC, Berrier J, Hewitt P, Berlin J, Reitman D, Nagalingam R, et al. Meta-analysis of randomized controlled trials as a method of estimating rare complications of non -steroidal anti - infl ammatory drug therapy. Aliment Pharmacol Ther 1988; 2: 9-26.
65. DerSimonian R. Parenteral nutrition with branched - chain amino acids in hepatic encephalopathy: meta analysis. Hepatology 1990; 11: 1083-4.
66. Naylor CD, O'Rourke K, Detsky AS, Baker JP. Parenteral nutrition with branched -chain amino acids in hepatic encephalopathy. A meta -analysis. Gastroenterology 1989; 97: 1033-42.
67. Erikkson LS, Conn HO. Branched-chain amino acids in hepatic encephalopathy. Gastroenterology 1990; 99: 604-7.
68. Thacker SB. Meta-analysis. A quantitative approach to research integration. JAMA 1988; 259: 1685-9.
69. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0, March 2011. www.cochrane -handbook.org (accessed July 2011).
70. Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak 2007; 7: 16.
71. Bernstein F. The retrieval of randomized clinical trials in liver diseases from the medical literature: manual versus MEDLARS searches. Controlled Clin Trials 1988; 9: 23-31.
72. Dickersin K, Hewitt P, Mutch L, Chalmers I, Chalmers TC. Perusing the literature: comparison of MEDLINE searching with a perinatal trials database. Controlled Clin Trials 1985; 6: 306-17.
73. Poynard T, Conn HO. The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Controlled Clin Trials 1985; 6: 271-9.
74. Eisinga A, Siegfried N, Clarke M. The sensitivity and precision of search terms in Phases I, II and III of the Cochrane Highly Sensitive Search Strategy for identifying reports of randomized trials in medline in a specifi c area of health care -HIV/AIDS prevention and treatment interventions. Health Info Libr J 2007; 24: 103-9.
75. Biondi-Zoccai GG, Agostoni P, Abbate A, Testa L, Burzotta F. A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol 2005; 34: 224-5.
76. Huston P, Moher D. Redundancy, disaggregation, and the integrity of medical research. Lancet 1996; 347: 1024-6.
77. Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbe KA. Incorporating variations in the quality of individual randomized trials into meta -analysis. J Clin Epidemiol 1992; 45: 255-65.
78. Berard A, Bravo G. Combining studies using effect sizes and quality scores: application to bone loss in postmenopausal women. J Clin Epidemiol 1998; 51: 801-7.
79. MahonWA, Daniel EE. A method for the assessment of reports of drug trials. Can Med Assoc J 1964; 90: 565-9.
80. Verhagen AP, de Vet HCW, de Bie RA, Kessels AGH, Boers M, Bouter LM, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998; 51: 1235-41.
81. Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care 1996; 12: 195-208.
82. Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Controlled Clin Trials 1995; 16: 62-73.
83. Greenland S. Quality scores are useless and potentially misleading. Am J Epidemiol 1994; 140: 300-1.
84. Jüni P, Witschi A, Block R, Egger M. The hazards of scoring the quality of clinical trials: lessons for meta - analysis. JAMA 1999; 282: 1054-60.
85. Greenland S. Invited commentary: a critical look at some popular meta -analytic methods. Am J Epidemiol 1994; 140: 290-6.
86. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12.
87. Greenland S, O'Rourke K. On the bias produced by quality scores in meta -analysis, and a hierarchical view of proposed solutions. Biostatistics 2001; 2: 463-71.
88. The Cochrane Collaboration' s Tool for Assessing Risk of Bias, 2010. http://www.ohg.cochrane.org/forms/ Risk%20of%20bias%20assessment%20tool.pdf(accessed July 2011).
89. Berlin JA, Miles CG, Cirigliano MD, Conill AM, Goldmann DR, Horowitz DA, et al. Does blinding ofreaders affect the results of metaanalyses? Results of a randomized trial. Online J Curr Clin Trials 1997; Doc. No. 205.
90. Engels EA, Schmid CH, Terrin N, Olkin I, Lau J. Heterogeneity and statistical signifi cance in meta - analysis: an empirical study of 125 meta -analyses. Stat Med 2000; 19: 1707-28.
91. Jonathan JD. Issues in the selection of a summary statistic for meta -analysis of clinical trials with binary outcomes. Stat Med 2002; 21: 1575-600.
92. Localio AR, Margolis DJ, Berlin JA. Relative risks and confi dence intervals were easily computed indirectly from multivariable logistic regression. J Clin Epidemiol 2007; 60: 874-82.
93. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. New York, NY: Van Nostrand Reinhold, 1982.
94. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1: 43-6.
95. Tang J-L. Weighting bias in meta -analysis of binary outcomes. J Clin Epidemiol 2000; 53: 1130-6.
96. Chang BH, Waternaux C, Lipsitz S. Meta-analysis of binary data: which within study variance estimate to use? Stat Med 2001; 20: 1947-56.
97. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989; 8: 141-51.
98. Fleiss JL. The statistical basis of meta -analysis. Stat Methods Med Res 1993; 2: 121-45.
99. Follmann DA, Proschan MA. Valid inference in random effects meta -analysis. Biometrics 1999; 55: 732-7.
100. Aitkin M. Meta-analysis by random effect modelling in generalized linear models. Stat Med 1999; 18: 2343-51.
101. Frost C, Clarke R, Beacon H. Use of hierarchical models for meta -analysis: experience in the metabolic ward studies of diet and blood cholesterol. Stat Med 1999; 18: 1657-76.
102. Senn SJ. The many modes of META. Drug Inf J 2000; 34: 535-49.
103. Hedges LV, Vevea JL. Fixed- and random -effects models in meta -analysis. Psychol Methods 1998; 3: 486-504.
104. Villar J, Mackey ME, Carroli G, Donner A. Metaanalyses in systematic reviews of randomized controlled trials in perinatal medicine; comparison of fi xed and random effects models. Stat Med 2001; 20: 3635-47.
105. Carlin JB. Meta-analysis for 2 × 2 tables: a Bayesian approach. Stat Med 1992; 11: 141-58.
106. Larose DT, Dey DK. Grouped random effects models for Bayesian meta -analysis. Stat Med 1997; 16: 1817-29.
107. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random -effects meta -analysis: a comparative study. Stat Med 1995; 14: 2685-99.
108. Eddy DM, Hasselblad V, Shachter R. An introduction to a Bayesian method for meta -analysis: The confi - dence profi le method. Med Decis Making 1990; 10: 15-23.
109. Simon R. Overviews of randomized clinical trials. Cancer Treat Rep 1987; 71: 3-5.
110. Glasziou PP, Sanders SL. Investigating causes of heterogeneity in systematic reviews. Stat Med 2002; 21: 1503-11.
111. Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta -analysis. Stat Med 1998; 17: 841-56.
112. Berlin JA, Antman EM. Advantages and limitations of metaanalytic regressions of clinical trials data. Online J Curr Clin Trials 1994; Doc. No. 134.
113. Vanhonacker WR. Meta-analysis and response surface extrapolation: a least squares approach. Am Stat 1996; 50: 294-9.
114. Walker AM, Martin-Moreno JM, Artalejo FR. Odd man out: a graphical approach to meta -analysis. Am J Pub Health 1988; 78: 961-6.
115. Song F. Exploring heterogeneity in meta -analysis: is the L 'Abbe plot useful? J Clin Epidemiol 1999; 52: 725-30.
116. Fleiss JL. Analysis of data from multiclinic trials. Controlled Clin Trials 1986; 7: 267-75.
117. Takkouche B, Cadarso-Suarez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta -analysis. Am J Epidemiol 1999; 150: 206-15.
118. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta -analysis. Stat Med 2002; 21: 1539-58.
119. Higgins J, Thompson SG, Deeks J, Altman DG. Measuring inconsistency in meta -analysis. BMJ 2003; 327: 557-60.
120. Higgins J, Thompson SG, Deeks J, Altman DG. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002; 7: 51-61.
121. Thompson SG, Sharp SJ. Explaining heterogeneity in meta -analysis: a comparison of methods. Stat Med 1999; 18: 2693-708.
122. Sharp SJ, Thompson SG. Analysing the relationship between treatment effect and underlying risk in meta-analysis: comparison and development of approaches. Stat Med 2000; 19: 3251-74.
123. Schmid C, Lau J, McIntosh M, Cappelleri J. An empirical study of the effect of the control rate as a predictor of treatment effi cacy in meta -analysis of clinical trials. Stat Med 1998; 17: 1924-42.
124. Cook RJ, Walter SD. A logistic model for trend in 2 × 2 × kappa tables with applications to meta - analyses. Biometrics 1997; 53: 352-7.
125. Trikalinos TA, Ioannidis JP. Predictive modeling and heterogeneity of baseline risk in meta -analysis of individual patient data. J Clin Epidemiol 2001; 54: 245-52.
126. Schmid CH. Exploring heterogeneity in randomized trials via meta -analysis. Drug Inform J 1999; 33: 211-24.
127. Davey Smith G, Egger M, Phillips AN. Metaanalysis. Beyond the grand mean? BMJ 1997; 315: 1610-4.
128. Hennessy S, Berlin JA, Kinman JL, Margolis DJ, Marcus SM, Strom BL. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta - analysis and formal sensitivity analysis. Contraception 2001; 64: 125-33.
129. Bradburn MJ, Deeks JJ, Berlin JA, Russell LA. Much ado about nothing: a comparison of the performance of meta -analytical methods with rare events. Stat Med 2007; 26: 53-77.
130. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta -analysis of sparse data. Stat Med 2004; 23: 1351-75.
131. Dahabreh IJ, Economopoulos K. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 2008; 5: 116-20.
132. Curtin F, Altman DG, Elbourne D. Meta-analysis combining parallel and cross -over clinical trials. I: Continuous outcomes. Stat Med 2002; 21: 2131-44.
133. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross -over clinical trials, II: Binary outcomes. Stat Med 2002; 21: 2145-59.
134. Elbourne D, Altman DG, Higgins J, Curtin F, Worthington H, Vail A. Meta-analysis involving cross-over trials: methodological issues. Int J Epidemiol 2002; 31: 140-9.
135. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross -over clinical trials. III:The issue of carry -over. Stat Med 2002; 21: 2161-73.
136. Donner A, Klar N. Issues in the meta -analysis of cluster randomized trials. Stat Med 2002; 21: 2971-80.
137. Chinn S. A simple method for converting an odds ratio to effect size for use in meta -analysis. Stat Med 2000; 19: 3127-31.
138. Zucker D, Schmid CH, McIntosh MW, D'Agostino RB, Selker HP, Lau J. Combining single patient (N - of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J Clin Epidemiol 1997; 50: 401-10.
139. Nam I-S, Mengersen KL, Garthwaite P. Multivariate meta-analysis. Stat Med 2003; 22: 2309-33.
140. Cook R, Brumback BA, Wigg M, Ryan L. Synthesis of evidence from epidemiological studies with interval-censored exposure due to grouping. Biometrics 2001; 57: 671-80.
141. Shi J, Copas J. Meta-analysis for trend estimation. Stat Med 2004; 23: 3-19.
142. Brumback BA, Holmes LB, Ryan LM. Adverse effects of chorionic villus sampling: a meta -analysis. Stat Med 1999; 18: 2163-75.
143. Martin DO, Austin H. An exact method for meta - analysis of case -control and follow -up studies. Epidemiology 2000; 11: 255-60.
144. Light RJ, Pillemer DB. Summing Up: the Science of Reviewing Research. Cambridge, MA: Harvard University Press, 1984.
145. Devine EC, Cook TD. Effects of psycho -educational interventions on length of hospital stay: a meta - analytic review of 34 studies. In: Light RJ, ed. Evaluation Studies Review Annual, Vol. 8. Beverly Hills, CA: Sage, 1983.
146. Sterne JAC, Egger M. Funnel plots for detecting bias in meta -analysis: Guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-55.
147. Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases in meta - analysis. BMJ 2001; 323: 101-5.
148. Terrin N, Schmid CH, Lau J, Olkin I. Adjusting for publication bias in the presence of heterogeneity. Stat Med 2003; 22: 2113-26.
149. Rosenthal R. The fi le drawer problem and tolerance for null results. Psychol Bull 1979; 86: 638-41.
150. Iyengar S, Greenhouse JB. Selection models and the fi le -drawer problem. Stat Sci 1988; 3: 109-17.
151. Gleser LJ, Olkin I. Models for estimating the number of unpublished studies. Stat Med 1996; 15: 2493-507.
152. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta -analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
153. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
154. Dear KBG, Begg CB. An approach for assessing publication bias prior to performing a meta -analysis. Stat Sci 1992; 7: 237-45.
155. Hedges LV, Vevea JL. Estimating effect size under publication bias: small sample properties and robustness of a random effects selection model. J Educ Behav Stat 1996; 21: 299-332.
156. Vevea JL, Hedges LV. A general linear model for estimating effect size in the presence of publication bias. Psychometrika 1995; 60: 419-35.
157. Givens GH, Smith DD, Tweedie RL. Publication bias in meta -analysis: a Bayesian data -augmentation approach to account for issues exemplifi ed in the passive smoking debate. Stat Sci 1997; 12: 221-50.
158. Duval S, Tweedie R. Trim and fi ll: A simple funnel - plot-based method of testing and adjusting for publication bias in meta -analysis. Biometrics 2000; 56: 455-63.
159. De AC, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 2004; 351: 1250-1.
160. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its infl uence on apparent effi cacy. N Engl J Med 2008; 358: 252-60.
161. Valsecchi MG, Masera G. A new challenge in clinical research in childhood ALL: the prospective meta - analysis strategy for intergroup collaboration. Ann Oncol 1996; 7: 1005-8.
162. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Effi cacy and safety of cholesterol - lowering treatment: prospective meta -analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
163. Bucher HC, Guyatt GH, Griffi th LE, Walter SD. The results of direct and indirect treatment comparisons in meta -analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-91.
164. Dias S,Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta - analysis. Stat Med 2010; 29: 932-44.
165. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between -study heterogeneity and inconsistency in mixed treatment comparisons:Application to stroke prevention treatments in individuals with non -rheumatic atrial fi brillation. Stat Med 2009; 28: 1861-81.
166. Salanti G, Marinho V, Higgins JP. A case study of multiple-treatments meta -analysis demonstrates that covariates should be considered. J Clin Epidemiol 2009; 62: 857-64.
167. Temple RJ. The regulatory evolution of the integrated safety summary. Drug Inform J 1991; 25: 485-92.
168. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
169. FDA. FDA Drug Safety Podcast: FDA signifi cantly restricts access to the diabetes drug Avandia, 2010 September 28. http://www.fda.gov/Drugs/ DrugSafety/DrugSafetyPodcasts/ucm227511.htm (accessed July 2011).
170. Bracken MB. Rosiglitazone and cardiovascular risk. N Engl J Med 2007; 357: 937-8.
171. Cepeda MS, Cousins MJ, Carr DB. Musculoskeletal pain. In: Cepeda MS, Cousins MJ, Carr DB, eds. Fast Facts: Chronic Pain. Oxford: Health Press, 2007, pp. 70-96.
172. Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fi bromyalgia syndrome with antidepressants: a meta -analysis. JAMA 2009; 301: 198-209.
173. Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009; 339: b2880.
174. Pogue J, Walter SD, Yusuf S. Evaluating the benefi t of event adjudication of cardiovascular outcomes in large simple RCTs. Clin Trials 2009; 6: 239-51.
175. Webber DM, Montague TH, Bird NP. Meta-analysis of QTc interval -pooling data from heterogeneous trials. Pharm Stat 2002; 1: 17-23.
176. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta -analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248-54.
177. Berkey CS, Mosteller F, Lau J, Antman EM. Uncertainty of the time of fi rst signifi cance in random effects cumulative meta -analysis. Controlled Clin Trials 1996; 17: 357-71.
178. Lan KKG, Hu M, Cappelleri JC. Applying the law of iterated logarithm to cumulative meta -analysis of a continuous endpoint. Statistica Sinica 2003; 13: 1135-45.
179. Ziegler RG, Mayne ST, Swanson CA. Nutrition and lung cancer. Cancer Causes Control 1996; 7: 157-77.
180. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long -term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-9.
181. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta -analysis. Lancet 2004; 364: 2021-9.
182. Gandey A. Merck Fights Back. Medscape Medical News, 2005. http://www.medscape.com/viewarticle/ 538074 (accessed July 2011).
183. Turner E, Moreno SG, Sutton AJ. Ranking antidepressants. Lancet 2009; 373: 1760-2.
184. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its infl uence on apparent effi cacy. N Engl J Med 2008; 358: 252-60.
185. FDA. Statistical Review and Evaluation. Antiepileptic Drugs and Suicidality. http://www.fda.gov/ downloads/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/UCM 192556.pdf(accessed July 2011).
186. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Effi cacy and safety of cefepime: a systematic review and meta -analysis. Lancet Infect Dis 2007; 7: 338-48.
187. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectaladenoma prevention. N Engl J Med 2005; 352: 1071-80.
188. Proschan MA, Lan KKG, Wittes JT. Monitoring for safety. In: Proschan MA, Lan KKG, Wittes JT, eds. Statistical Monitoring of Clinical Trials. New York: Springer, 2010, pp. 155-74.
189. Song F, Altman DG, Glenny AM, Deeks J. Validity of indirect comparison for estimating effi cacy of competing interventions: empirical evidence from published meta -analyses. BMJ 2003; 326: 1-5.
190. Platt R,Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M. The new Sentinel Network - improving the evidence of medical -product safety. N Engl J Med 2009; 361: 645-7.
191. US Department of Health and Human Services. The Sentinel Initiative: A National Strategy for Monitoring Medical Product Safety, 2008. http:// www.fda.gov/Safety/FDAsSentinelInitiative/ ucm089474.htm (accessed July 2011).
192. US Department of Health and Human Services. FDA' s Sentinel Initiative - Ongoing Projects. http:// www.fda.gov/Safety/FDAsSentinelInitiative/ ucm203500.htm (accessed July 2011).
193. Platt R. FDA' s Mini-Sentinel Program, 2010. http:// www.brookings.edu/ ~/media/Files/events/ 2010/0111_sentinel_workshop/06%20Sentinel%20 Initiative%20Platt%20Brookings%2020100111% 20v05%20distribution.pdf(accessed July 2011).
194. Foundation for the National Institutes of Health. Observational Medical Outcomes Partnership. http://omopfnihorg/?q=node/22 (accessed July 2011).